Rapport Therapeutics inuuna ang simula ng RAP-219 Phase 3 sa Q2 2026

FDA clearance pagkatapos ng End-of-Phase-2 meeting ay nagpapahintulot sa RAP-219 na direktang umabante sa registrational trials para sa focal onset seizures. Ang kompanya ay inuuna ang simula ng Phase 3 program mula Q3 2026 patungong Q2 2026. Isang open-label long-term safety extension ay nagsimula nang mag-enroll ng mga pasyente mula sa nakumpletong Phase 2a study.

Mahahalagang fact

Na-file: Ene 7, 2026, 12:30 PM
Kaganapan: Pagbabago sa trial registry
Direksyon: Positibo
Kumpanya: RAPPRapport Therapeutics
Asset: RAP-219
Pinagmulan: SEC 8-K
Kumpiyansa: May source

Sipi mula sa source

EX-99.1 2 rapp-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second quarter of 2026 On strength of RAP-219 Phase 2a FOS data, epilepsy portfolio expanded with new program in primary generalized tonic-clonic seizures (PGTCS) Phase 2 trial in bipolar mania, long-acting injectable, and other pipeline programs continuing to progress BOSTON and SAN DIEGO, January 7, 2026 (GLOBE NEWSWIRE) – Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Compa

SEC 8-K